Vir Biotechnology, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Vir Biotechnology, Inc. (VIR) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $23.55 million as of 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-02-23
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $23.55M.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $25.62M.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $31.87M.
- 2022-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $38.38M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $23.55M 10-K · filed 2026-02-23 |
| 2024-12-31 | $25.62M 10-K · filed 2025-02-27 |
| 2023-12-31 | $31.87M 10-K · filed 2024-02-26 |
| 2022-12-31 | $38.38M 10-K · filed 2023-02-28 |
| 2022-09-30 | $40.11M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $41.93M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $43.59M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $45.26M 10-K · filed 2022-02-28 |
| 2021-09-30 | $36.74M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $38.14M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $39.52M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $40.95M 10-K · filed 2021-02-25 |
| 2020-09-30 | $2.67M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $2.93M 10-Q · filed 2020-08-11 |
| 2020-03-31 | $3.24M 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |